This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Real-World Outcomes of Once-Daily Risperidone Dosing

Sanjay Gupta, MD; Sadiq Al-Samarrai, MD; Prakash S. Masand, MD; Barbara J. Lentz, RN; Peggy J. Keller, RNC, MS; and Thomas M. Droney, RN

Published: April 1, 2000

Article Abstract

Background: Recent reports have shown that risperidone, which has established antipsychotic efficacy, is effective and safe in a once-daily dosing regimen.

Method: The efficacy and safety of once-daily risperidone were assessed in a retrospective study of 27 patients with a variety of psychiatric disorders who were attending a community day treatment program. Their DSM-IV diagnoses included schizophrenia, schizoaffective disorder, bipolar disorder, major depression with psychosis, and posttraumatic stress disorder. They had received once-daily risperidone for a mean of more than 18 months.

Results: Disorders of most patients were controlled with once-daily dosages of 1 to 6 mg/day of risperidone. The nighttime once-daily risperidone dosage was well tolerated by patients. In addition, there was no increase in antipsychotic-related side effects, and compliance was enhanced.

Conclusion: Risperidone was well tolerated, and no patient needed antiparkinsonian medications even at high dosages of risperidone once daily.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 2

Quick Links: